KKL 顾客使用本产品发表的 2 篇科研文献

Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).

Treatment of HUVECs with Adalimumab for up to 12 hours shows no adverse effect on their cell viability, even with a 10-fold higher concentration of Adalimumab than used in this study.

The elimination half-life (t_1/2) of Adalimumab is long (~20 days). The enriched fluorescent-labelled adalimumab is observed mainly in major Oil red O-positive lesions documenting good tissue penetration of the drug into the atherosclerotic plaque, without background fluorescence of the vessel wall after vehicle control injection into hypercholesterolemic Ldlr mice.

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.